Related Experiment Video
Updated: Mar 16, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Unplanned pregnancy on a direct oral anticoagulant (Rivaroxaban): A warning
1Department of Haematology, Leicester Royal Infirmary, Leicester, UK; Lincoln County Hospital, Lincoln, UK.
Abstract:
Direct oral anticoagulants (DOACs or NOACs -non-vitamin K oral anticoagulants), as the name suggests, are oral anticoagulants with a direct inhibitory action either against factor X or factor II (thrombin). Pregnant women were excluded from participating in all the large trials of the DOACs and they are considered contra-indicated in pregnancy and breast feeding. We present a case of inadvertent exposure to rivaroxaban in a woman who presented at 25 weeks' gestation. The management of her pregnancy and delivery is described, and the previous published case reports are reviewed with a discussion about the use of DOACs in woman of childbearing age.
Insights
Direct oral anticoagulants (DOACs) are not recommended during pregnancy. This case report details the management of inadvertent rivaroxaban exposure in a 25-week pregnant woman, reviewing current literature.
Area of Science:
- Pharmacology
- Obstetrics
- Hematology
Background:
- Direct oral anticoagulants (DOACs) are increasingly used for thromboprophylaxis and treatment.
- DOACs are contraindicated in pregnancy due to limited safety data and potential risks.
- Pregnant women were excluded from major clinical trials involving DOACs.
Observation:
- A case of inadvertent exposure to rivaroxaban, a DOAC, occurred at 25 weeks' gestation.
- The management of the pregnancy, including delivery, was carefully monitored.
- This case highlights the challenges of managing DOAC exposure during pregnancy.
Findings:
- Review of previous case reports on DOAC use in pregnant women.
- Discussion on the safety and management of rivaroxaban exposure during gestation.
- Analysis of the clinical course and outcome of the presented case.
Implications:
- Informs clinical practice regarding the management of accidental DOAC exposure in pregnant patients.
- Highlights the need for further research on DOAC safety in pregnancy.
- Contributes to the understanding of anticoagulation strategies in pregnant women of childbearing age.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis IV: Nursing Management

